Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)

This program funds secondary analysis and integration of existing data to answer cancer research questions about risk, prevention, survival, treatment response, surveillance, behavior, health care delivery, and related outcomes. Eligible applicants include many U.S. and non-U.S. organizations, including nonprofits, universities, governments, small businesses, and foreign organizations, but applications involving foreign subawards or subcontracts are not allowed. Awards are grants with direct costs limited to $275,000 over two years, with no more than $200,000 in direct costs in any single year, and the project period may be up to 2 years. No cost sharing is required, clinical trials are not allowed, and up to 10% of the budget may be used for new data generation only to validate key findings.

✳ AI-generated summary — verify against the announcement

• Education
• Health
• Research & Discovery
• Researchers & Scholars
• Biomedical & Disease Research

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments